Andrographis (Expanded) for Immune Function

Research suggests that the evidence for Andrographis paniculata as a support for immune function in the context of COVID-19 is limited and mixed. The available studies include one small randomized controlled trial and one retrospective observational study, both focused on mild COVID-19 outcomes such as pneumonia rates and inflammatory markers. The RCT reported a statistically significant reduction in one inflammatory marker (CRP) among those receiving the herb, along with some favorable but non-significant trends, while the larger retrospective study found no meaningful protective effect against pneumonia development. Both studies acknowledge substantial limitations — including small or methodologically constrained designs — and their authors call for more rigorous, adequately powered trials before any firm conclusions about immune benefits can be drawn.